{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'Levosalbutamol/Levalbuterol Nebulizer Solution -Total Daily Dose (mg)', 'Number of Puffs*', '1.25', '4', '2.5', '8', '3.75', '12', '5', '16', '*Conversion factor: levosalbutamol/levalbuterol nebulizer solution (1.25 mg) corresponds to 4 puffs', 'Example of levosalbutamol/levalbuterol nebulizer-to-puff Conversion: Patient received', '3 evosalbutamol/levalbuterol nebulizer treatments (1.25 mg/treatment) between 7 and', '11 AM. Total daily = 3.75 mg or 12 puffs.', 'After conversion of nebulizer-to-puff, and for every instance that the number of puffs is', '>6 additional puffs of salbutamol/albuterol or levosalbutamol/levalbuterol in a 24-hour period', '(compared to Baseline) on 2 consecutive days in any week, a LOAC event should be documented.', '8.3', 'BLINDING PROCEDURES', '8.3.1 Methods of blinding', 'Dupilumab and placebo will be provided in identically matched pre-filled syringes. To protect the', 'blind, each treatment kit of 0.67 or 1.14 mL (dupilumab/placebo) glass pre-filled syringes will be', 'prepared such that the treatments (dupilumab and its matching placebo) are identical and', 'indistinguishable and will be labeled with a treatment kit number. The randomized treatment kit', 'number list will be generated by Sanofi.', 'Patients and Investigators will be blinded to assigned treatment. Patients and Investigators will not', 'be blinded to dose regimen as the volumes are different.', 'Patient(s)/parent(s)/caregiver(s)/legal guardian(s) Investigators, and study site personnel will not', 'have access to the randomization (treatment codes) except under circumstances described in', 'Section 8.3.2.', '8.3.2 Randomization code breaking during the study', 'In case of an AE, the code should only be broken in circumstances when knowledge of the IMP is', 'required for treating the patient.', 'Code breaking can be performed at any time by using the proper module of the interactive voice', 'response system (IVRS)/interactive web response system (IWRS) and/or by calling any other', 'phone number provided by the Sponsor for that purpose. If the blind is broken, the Investigator', 'should document the date, time of day and reason for code breaking.', 'Property of the Sanofi Group - strictly confidential', 'Page 53', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'Patient withdrawal will only occur when the code break call is made at the site level, not the study', 'level. This means that if the Emergency Unblinding transaction is performed by the Investigator', '(ie, at the site level), then the subject will be withdrawn from treatment. However, if the', 'Emergency Unblinding transaction is performed by the Global Safety Officer (GSO) (ie, at the', 'study level, as the GSO is not site based), then the subject will not be withdrawn from treatment.', 'At the facilities where the systemic drug concentration measurements, ADAs and selected', 'biomarkers are determined, the samples will be analyzed prior to data base lock leading to', 'unblinding of responsible bioanalysts. Bioanalysts are excluded from the clinical trial team.', 'Patient(s)/parent(s)/caregiver(s)/legal guardian(s) Investigators, and site personnel will not have', 'access to assay results for immunoglobulins (immunoglobulin G (IgG), IgG subclasses,', 'Immunoglobulin A (IgA), IgM and IgE) after randomization and first administration of study', 'medication, because these values have the potential for unblinding. Furthermore, neither', 'atient(s)/parent(s)/caregiver(s)/legal guardian(s), Investigators nor site personnel will have access', 'to total IgE, antigen-specific IgE, antigen-specific IgG4, Thymus and Activation-Regulated', 'Chemokine (TARC) while the study is ongoing, as the related data are not essential for patient', 'care and have the potential for unblinding.', 'The DMC will receive blinded by treatment group or unblinded (if necessary) confidential reports', 'from an independent statistician for review, which have to be handled strictly confidentially. None', 'of these reports can be delivered to unauthorized persons.', '8.4', 'METHOD OF ASSIGNING PATIENTS TO TREATMENT GROUP', 'A randomized treatment kit number list will be generated centrally by Sanofi. The investigational', 'product (dupilumab or placebo) will be packaged in accordance with this list.', 'The Sanofi Clinical Supplies team will provide the randomized treatment kit number list and the', 'Study Biostatistician will provide the randomization scheme to the centralized treatment', 'allocation system (IVRS/IWRS). This centralized treatment allocation system will generate the', 'patient randomization list according to which it will allocate the treatments to the patients.', 'Patients who meet the entry criteria will be randomized to receive either dupilumab or placebo.', 'Rescreening is not permitted if the patient fails to meet inclusion criteria. Patients who meet', 'exclusion criteria may be rescreened once during the open Screening Period of the study. There is', 'no requirement for a waiting period between the screen-failure date and the rescreening date. The', 'IVRS/IWRS report will flag rescreened patients. Patients that are rescreened must have', 'parent(s)/caregiver(s)/legal guardian(s) resign a new ICF and sign a new IAF, and all Screening', 'Visit 1 procedures must be repeated.', 'The Investigator obtains treatment kit numbers at randomization and subsequent scheduled visits', 'via an IVRS/IWRS that will be available 24 hours a day.', 'Property of the Sanofi Group - strictly confidential', 'Page 54', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}